DEA Slaps Another Year on Five Frankenstein Benzo Drugs
Published Date: 7/25/2025
Rule
Summary
The DEA is extending the temporary Schedule I status for five designer drugs—clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam—for one more year or until permanent rules are set. This means anyone making, selling, or using these drugs will keep facing strict legal controls and penalties. If you work with these substances, get ready to follow the same tough rules for now!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
One-Year Extension of Schedule I Controls
The DEA is extending the temporary Schedule I status of clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam for one year or until permanent rules are set. If you make, sell, import, export, research, teach about, chemically test, or possess these drugs, you will continue to be subject to the strict regulatory controls and administrative, civil, and criminal penalties that apply to Schedule I substances.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13364 — Schedules of Controlled Substances: Temporary Placement of 5,6- Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act
Starting July 1, 2026, the DEA is temporarily putting four new substances—5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move helps keep these potentially dangerous drugs off the streets while the DEA studies them further.
2026-13145 — Importer of Controlled Substances Application: Almac Clinical Services Incorp. (ACSI)
Almac Clinical Services Incorp. (ACSI) wants to become an official importer of certain controlled substances, including psilocybin and oxycodone. This affects drug manufacturers and others in the industry who can comment or request a hearing by July 30, 2026. No direct costs are mentioned, but the decision could impact how these substances enter the U.S. market.
2026-13144 — Importer of Controlled Substances Application: Catalent Pharma Solutions, LLC
Catalent Pharma Solutions wants to become an official importer of some powerful controlled substances like LSD and psilocybin. People who make or use these drugs can share their thoughts or ask for a hearing by July 30, 2026. This move could impact companies involved in these substances and the government’s control over them.
2026-12653 — Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
Previous / Next Documents
Previous: 2025-14013 — Program Originating FM Broadcast Booster Stations
The FCC just gave the green light for FM booster stations to create their own content permanently, making it easier for local radio to shine. Broadcasters using these boosters will need to file a new form to keep the FCC in the loop. These changes kick in soon, so stations should get ready to boost their voices without extra costs!
Next: 2025-14040 — Amendment of VOR Federal Airways V-38, V-133, and V-144, and Revocation of VOR Federal Airway V-214 in the Vicinity of Zanesville, OH
The FAA is updating some flight paths near Zanesville, Ohio, by changing routes V-38, V-133, and V-144, and removing route V-214. This happens because the Zanesville navigation beacon is being turned off as part of a plan to modernize air travel. Pilots flying in this area will need to follow the new routes starting soon, but there’s no extra cost for travelers.